<DOC>
	<DOCNO>NCT00112476</DOCNO>
	<brief_summary>This phase I trial study side effect best dose temsirolimus give together bryostatin 1 treat patient unresectable metastatic solid tumor . Drugs use chemotherapy , temsirolimus bryostatin 1 , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell .</brief_summary>
	<brief_title>Temsirolimus Bryostatin 1 Treating Patients With Unresectable Metastatic Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose recommended phase II dose temsirolimus give together bryostatin 1 patient unresectable metastatic solid tumor . II . Determine dose-limiting toxic effect regimen patient . SECONDARY OBJECTIVES : I. Correlate extent duration inhibition p70^S6kinase phosphorylation peripheral blood mononuclear cell tumor growth reduction patient . II . Correlate phosphorylation total phospho-AKT total phospho ribosomal S6 protein ( indicator mTOR activation ) antitumor effect regimen patient . III . Correlate tumor expression phospho-ERK1 -ERK2 antitumor effect regimen patient . IV . Determine pharmacokinetics regimen patient . OUTLINE : This dose-escalation study temsirolimus . Patients receive bryostatin 1 IV 1 hour day 1 , 8 , 15 , 22 temsirolimus IV 30 minute day 8 , 15 , 22 course 1 . On subsequent course patient receive bryostatin 1 temsirolimus day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos temsirolimus maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically confirm solid tumor , include melanoma renal cell carcinoma Metastatic unresectable disease Must evidence residual , recurrent , metastatic disease radiography Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique ( CT scan , MRI , xray ) OR ≥ 10 mm spiral CT scan Must show clear evidence disease progression within lesion site measurable disease within previously irradiate volume Standard curative palliative measure exist OR longer effective No history know brain metastasis Performance status ECOG 01 At least 3 month WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 AST ALT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin normal Creatinine ≤ 1.5 time ULN Creatinine clearance ≥ 50 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Fasting cholesterol ≤ 350 mg/dL* Triglycerides ≤ 400 mg/dL* Not pregnant nursing Negative pregnancy test Fertile female patient must use effective contraception ≥ 1 month , , ≥ 3 month completion study treatment ( ≥ 3 month completion study treatment male patient ) No history allergic reaction attribute compound similar chemical biological composition study drug No ongoing active bacterial viral infection No psychiatric illness social situation would preclude study compliance No dementia alter mental status would preclude give informed consent No uncontrolled illness More 3 week since prior immunotherapy Prior biological therapy ( e.g. , interferon interleukin 2 , vaccine , antibodybased tyrosine kinase inhibitor ) allow No concurrent prophylactic hematopoietic colonystimulating factor except epoetin alfa No prior cytotoxic chemotherapy No prior bryostatin 1 , temsirolimus , everolimus , AP23573 malignancy More 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No concurrent steroid except topical inhale use No concurrent experimental agents No prior radiotherapy &gt; 25 % bone marrow More 3 week since prior radiotherapy More 3 week since prior major surgery , include nephrectomy Minor surgical procedure allow Recovered prior therapy More 3 week since prior anticancer investigational agent Concurrent CYP3A4 inducer inhibitor allow provided patient stable dose ≥ 1 week study entry No concurrent combination antiretroviral therapy HIVpositive patient No concurrent antineoplastic agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>